2021 ACMG Annual Clinical Genetics Meeting - Product Theaters-Introducing Panaroma AI: SNP-based NIPT innovation with Artificial Intelligence

Introducing Panaroma AI: SNP-based NIPT innovation with Artificial Intelligence

Video Transcription

Video Summary

The video features Sheetal Parmar, the Vice President of Medical Affairs for Natera, discussing Natera's innovations in SNP-based NIPT technology and introducing Panorama AI. Parmar addresses several questions throughout the video, including the differences between SNP-based NIPT and other NIPTs, the features and improvements of Panorama AI, the SNP-based micro-deletion and aneuploidy registry (SMART) study where Panorama AI was validated, the performance improvements observed in the SMART study, and the clinical implications of these improvements. Parmar explains that SNP-based NIPT analyzes cell-free DNA in the blood of pregnant women and distinguishes between maternal and placental DNA, allowing for better detection of chromosomal abnormalities and additional capabilities such as twin zygosity determination. The SMART study validates the performance of Panorama AI, showing improved accuracy, reduced no-call rates, and better detection of 22q11.2 deletion syndrome. These advancements provide important clinical implications for screening and counseling pregnant women. Credits: Video transcript by Natera.

Asset Subtitle

Natera

Keywords

SNP-based NIPT technology

Panorama AI

SMART study

chromosomal abnormalities

pregnant women

clinical implications